News

HDA UK Media And Political Bulletin – 21 September 2017

Media Summary

Patients could face medicine shortage

Sky News, Paul Kelso, 21 September 2017

 

Sky News reports on a warning issued by the pharmaceutical industry that British patients could face drugs shortages and long delays for new medicines as a result of the European Medicines Agency being forced to leave the UK after Brexit. Drugs companies told Sky News that the EMA’s departure will damage the UK’s position as a centre of drugs innovation and as a result patients may have to wait for new treatments that currently reach the British market first.

 

DH will consult public on changes to pharmacy supervision law

Chemist and Druggist, Grace Lewis, 20 September 2017

 

Chemist and Druggist reveals that the Department of Health (DH) will set up a programme board that will be responsible for holding a public consultation on pharmacy supervision “before it settles on a firm set of proposals”. The DH programme board responsible for “rebalancing” medicines legislation and pharmacy regulation “will consult…a range of pharmacy stakeholders, including patients and the public” before submitting changes to pharmacy supervision legislation the Department of Health has confirmed to Chemist and Druggist.

 

 

Parliamentary Coverage

There is no Parliamentary Coverage today. 

Full Coverage

 

Patients could face medicine shortage

Sky News, Paul Kelso, 21 September 2017

 

British patients could face drugs shortages and long delays for new medicines as a result of the European Medicines Agency being forced to leave the UK after Brexit, the pharmaceuticals industry has warned.

 

Drugs companies have told Sky News that the EMA’s departure will damage the UK’s position as a centre of drugs innovation and in turn mean patients have to wait for new treatments that currently reach the British market first.

 

The EMA, which licences medicines for 500 million Europeans and oversees an industry worth £200bn, has been based in London for more than 20 years, but will leave its Canary Wharf headquarters after March 2019.

 

The agency is seen as a prestigious and valuable asset by other European nations and there is fierce competition to succeed London between cities from 19 of the EU’s 27 remaining nations.

 

DH will consult public on changes to pharmacy supervision law

Chemist and Druggist, Grace Lewis, 20 September 2017

 

A Department of Health (DH) programme board will hold a public consultation on pharmacy supervision “before it settles on a firm set of proposals”, the government has told C+D.

 

The DH programme board responsible for “rebalancing” medicines legislation and pharmacy regulation “will consult…a range of pharmacy stakeholders, including patients and the public” before submitting changes to pharmacy supervision legislation, it confirmed to C+D yesterday (September 19).

 

C+D exclusively revealed last week that detailed proposals for pharmacy technicians to be handed legal responsibility for supervising the supply of prescription-only medicines (POMs) have been submitted to the DH programme board.

 

A working group, established by the UK’s four chief pharmaceutical officers, also suggested amending legislation to allow a pharmacy technician to, in the pharmacist’s absence, undertake the “supervision role” of determining when medicine supplies can go ahead and “overseeing the activities of other, non-regulated, pharmacy staff”, according to confidential documents seen by C+D.

 

The DH told C+D yesterday that the programme board “is continuing to consider the role of registered pharmacy technicians”.

 

When will ministers get involved?

On Monday (September 18), C+D reported that the DH failed to confirm whether Jeremy Hunt knew about pharmacy supervision proposals, a month after he tried to “reassure” a pharmacist on the subject.

 

Speaking to C+D yesterday, a DH spokesperson stressed that only after a public consultation has been held “will proposals be submitted to ministers for consideration”.

HDA UK Media And Political Bulletin – 21 September 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?